Results 31 to 40 of about 10,491 (187)

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.

PLoS ONE, 2019
Antiretroviral agents are approved in Japan based on non-clinical and clinical data reported from overseas. Neither the long-term tolerability nor the effectiveness of raltegravir or other integrase strand transfer inhibitors in Japan is known.
Naho Kuroishi, Asuka Watananbe, Ryuta Sakuma, Daniel J Ruzicka, Mitsuyoshi Hara   +4 more
doaj   +1 more source

Raltegravir in the management of HIV-infected patients

, 2008
Hans-Jürgen StellbrinkICH and IPM Study Center Hamburg, Hamburg, GermanyAbstract: Raltegravir has recently been licensed for the treatment of HIV-1 infection.
Hans-Jürgen Stellbrink, Hans-Juergen Stellbrink   +1 more
core   +1 more source

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence

Frontiers in Microbiology, 2019
The human immunodeficiency virus type 1 (HIV-1) has several proteins of therapeutic importance, many of which are currently used as drug targets in antiretroviral therapy. Among these proteins is the integrase, which is responsible for the integration of
Lucas de Almeida Machado, Marcelo Ferreira da Costa Gomes, Ana Carolina Ramos Guimarães   +2 more
doaj   +1 more source

Role of raltegravir in the management of HIV-1 infection

, 2011
N Lance Okeke1, Charles Hicks21Duke University Medical Center, Department of Hospital Medicine, Durham Regional Hospital, Durham, North Carolina, USA; 2Duke University School of Medicine, Durham, NC, USAAbstract: The development of multiple agents with ...
null Okeke, Okeke NL, Charles Hicks, Hicks C   +3 more
core   +1 more source

Human papillomavirus persistence and clearance in women living with HIV: A five‐year retrospective analysis from an Italian university center

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
In women living with HIV, HPV clearance occurred after a mean of approximately 2 years under antiretroviral therapy. Baseline positivity for the high‐risk HPV pool was associated with delayed clearance, suggesting that HPV genotype may influence viral persistence more than immunovirological status in clinically stable patients.
Annunziata Carlea, Dario Colacurci, Giorgia D'Apice, Laura Letizia Mazzarelli, Massimiliano Pellicano, Luigi Falco, Ginevra Sepe, Oriana Imperatore, Giuseppe Maria Maruotti, Maurizio Guida, Laura Sarno   +10 more
wiley   +1 more source

Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2019
Background: The life expectancy for HIV-infected individuals has improved dramatically because of improvements in antiretroviral therapy (ART). Today, a simplified two-drug regimen enhances adherence and treatment satisfaction by reducing adverse effects.
Yinqiu Huang, Yinqiu Huang, Xiaojie Huang, Hui Chen, Hao Wu, Yaokai Chen, Yaokai Chen   +6 more
doaj   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

Journal of Virus Eradication, 2015
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak   +16 more
doaj   +1 more source

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

HIV Research & Clinical Practice, 2021
Objectives: Tenofovir DF (TDF) remains one of the preferred backbone agents for naïve HIV patients starting antiretroviral treatment (ART). The impact of TDF on renal function and metabolic parameters may vary by anchor agent.
Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle   +8 more
doaj   +1 more source